After April removals from the restricted list, where do peptides actually stand? A May pharmacy update gave a clear answer: BPC-157 and others sit in a gray zone, neither prohibited nor clearly permitted.
A May 2026 pharmacy update clarified that peptides such as BPC-157 and TB-500, removed from the FDAs restricted Category 2 list in April, were not moved to Category 1 (permitted for compounding) and are not FDA-approved or recognized by a USP monograph. That leaves them in a regulatory gray zone, neither clearly prohibited nor clearly authorized.
April brought a headline that peptides were coming off the FDAs restricted list, raising hopes of easy access.
A May pharmacy update offered the sober, precise picture.
Following the April 2026 removal of BPC-157, TB-500, and CJC-1295 from the FDAs Category 2 list, after the withdrawal of their nominations, a May pharmacy analysis clarified the resulting status. Crucially, the FDA did not move these peptides to Category 1, the list of substances permitted for compounding, and none is an FDA-approved drug or has a recognized USP/NF monograph. The result is a regulatory gray zone: the peptides are no longer formally on the do-not-compound restricted list, yet they are not affirmatively authorized for compounding either.
May commentary across pharmacy and regulatory sources reinforced that fundamental conditions had not changed: these remain unapproved drugs, not lawful dietary supplement ingredients, and an advisory committee review of specific peptides was still scheduled for later in 2026. Removal from a restricted list, in short, did not equal a green light.
For consumers, the gray-zone reality is a caution against assuming the April news made peptides freely or safely available. Status varies by peptide, pharmacy, and state, and the absence of FDA approval or a quality monograph means consistency and safety are not assured. The prudent path is physician-supervised care through licensed pharmacies where lawful, and skepticism toward any vendor claiming these peptides are now approved or unrestricted.
Watch the advisory-committee review expected later in 2026 and any formal FDA rulemaking, which would clarify whether specific peptides become eligible for compounding. Until then, the gray zone persists. For consumers, the steady approach is to follow official FDA actions rather than marketing, to rely on qualified providers, and to remember that not approved and not clearly permitted are very different from safe and available.